Keynote speakers



Leroy Hood, MD. Ph.D. CEO Phenome Health Seattle I USA



Hitoshi Nakagama, Prof. President National Cancer Center Tokyo | Japan



Annette Peters, Prof. Host Institute of Epidemiology Helmholtz Munich | Germany



Rima Kaddurah-Daouk, Prof. Duke University School of Medicine Durham | USA



Christof von Kalle, Prof. CSC | Berlin Institute of Health Berlin | Germany



Host
Executive Director
Tohoku Medical Megabank
Organization, Sendai Hapan

Masayuki Yamamoto, Prof.



Jessica Lasky-Su, Ass. Prof. Host Harvard Medical School Boston | USA

Sendai

Munich

Boston

22 hours continuous livestream

Supported by









BRIGHAM HEALTH





Genomi

HelmholtzZentrum münchen
German Research Center for Environmental Health



BRIGHAM AND WOMEN'S HOSPITAL









Register now

https://biocrates.com/2022-population-health-event/

For questions please contact cohortevent@biocrates.com



Sendai | Virtual event

October 12th, 2022 | 8:45 a.m. - 17:15 p.m. JST

Biobanks - 08:45 a.m. JST

08:45-09:00

Welcome and opening

Masayuki Yamamoto, Prof.

Executive Director

Tohoku Medical Megabank Organization, Sendai | Japan

Matthias Scheffler, Dr.

Chief Business Officer | Chief Scientific Officer of biocrates life sciences, Innsbruck | Austria

09:00-09:25

Keynote lecture: Collaboration and integration of population-based and disease-based cohort studies are essential to the establishment of precision cancer medicine and personalized prevention

Hitoshi Nakagama, Prof.

President of the National Cancer Center, Tokyo | Japan

09:25-09:50

Tohoku Medical Megabank Project: Cohort and Biobank

Seizo Koshiba, Prof.

Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai | Japan

09:50-10:15

Taiwan Biobank resources for population health research Chang Chung-ke, Ph.D.

Chief Administrative Officer and Chief Information Security Officer of Taiwan Biobank, Taipei | Taiwan

10:15-10:40

Singapore National Precision Medicine Program

John Chambers, Prof.

Lee Kong Chian School of Medicine,

Nanyang Technological University | Singapore

10:40-11:05

BioBank Japan: 20 years of disease-oriented cohort study towards genomic and multi-omic study

Takayuki Morisaki, Prof.

BioBank Japan, The Institute of Medical Science,

University of Tokyo | Japan

Coffee break 11:05-11:20

Technology – 11:20 a.m. JST

11:20-11:45

BRAINCommons: A research and discovery platform paving the way for pan-cohort analysis

Maryan Zirkle, Ph.D.

BRAIN Commons of Cohen Veterans Bioscience,

Edgewater | USA

11:45-12:10

Study design for metabolomics research: challenges in biomedicine

Jerzy Adamski, Prof.

Chief Scientific Officer of Metaron Diagnostics,

Munich | Germany, National University of Singapore | Singapore

12:10-12:35

Large-scale cohort study using targeted metabolomics kit and its application to gynecological cancer biomarker discovery Eiji Hishinuma, Ass. Prof.

Advanced Research Center for Innovations in the Next-Generation Medicine, Tohoku University, Sendai | Japan

Lunch Japan 12:35-13:25

(Multi)Omics - 13:25 p.m. JST

13:25-13:50

mGWAS: A powerful approach for metabolic fine mapping of genetic risk loci

Karsten Suhre, Prof.

Director of Bioinformatics Core of Weill Cornell Medicine,

Doha | Qatar

13:50-14:15

Statistical genetics, disease biology, drug discovery, and personalized medicine

Yukinori Okada, Prof.

Department of Statistical Genetics, Osaka University Graduate School of Medicine | Japan

14:15-14:40

Pan-cancer analysis of pre-diagnostic blood metabolite concentrations

Vivian Viallon, Ph.D.

Nutrition and Metabolomics Branch of the

International Agency for Research on Cancer (IARC), Lyon | France

14:40-15:05

Plasma biomarker studies on cancer within the Japan Public Health Center-based prospective study

Motoki Iwasaki, Ph.D.

Director of Epidemiology Research for the National Cancer Center, Tokyo | Japan

Coffee break 15:05-15:20

Pan-cohort | Precision medicine – 15:20 p.m. JST

15:20-15:45

Evaluation of spike protein epitopes by assessing dynamics of the humoral immune responses in the moderate COVID-19

Sigi Liu, Prof.

Chief Scientist Protein Sciences of BGI, Shenzhen | China

15:45-16:10

Imaging metabolomics reveals roles of reactive sulfur species in pancreatic cancer chemoresistance

Makoto Suematsu, Prof.

Department of Biochemistry

Keio University School of Medicine, Tokyo | Japan

16:10-16:35

Metabolomics and cardiometabolic risk: Findings from the international collaborative analysis

Toru Takebayashi, Prof.

Preventive Medicine and Public Health School of Medicine for Keio University, Tokyo | Japan

16:35-17:00

Keynote lecture: The impact of population-based studies on population health | Precision medicine

Masayuki Yamamoto, Prof.

Executive Director

Tohoku Medical Megabank Organization, Sendai | Japan

17:00-17:15

Summary and closing Japan session

Masayuki Yamamoto/Matthias Scheffle

Welcome Europe session